The network has none of the five drugs against obesity approved by Anvisa
The National Commission for the incorporation of technologies in the Unified Health System (CONITEC), an agency of the Ministry of Health, has opened a consultation know the opinion of the population on the inclusion of the semaglutado Among the medicines offered by Sus. The substance, used in the treatment of type 2 diabetes and obesity, is the basis of Ozempic and from Wegovy.
The proposal discusses the free offer of 2.4 mg of WEGOVY Formula for patients with patients with patients with patients obesity Grade II and III, without diabetes, 45 years old and with established cardiovascular diseases, such as myocardial infarction or Race (race) Before. The community can send experiences and evaluations of experience Online form until June 30th.
If approved, this will be the first pharmacological treatment for the disease available in the public network. Currently, Sus only offers approaches such as food orientation, incentive to physical activity and psychological support e Bariatric surgery in specific cases.
First opinion
In the analysis presented to Conditec by the pharmacist New NordiskThe annual cost per patient would be $ 34,000 and each would use the drug for two years. In this scenario, expenses on five years would be $ 3.4 billion to $ 3.9 billion.
Conitec, however, evaluated that the costs would be different. Considering that obesity is a chronic disease and that the traffic semaglutado would have been used continuously, the commission estimated that the expense for patients would be $ 300,000 and the amount in five years could reach $ 7 billion.
Due to these numbers, the Commission decided, in a meeting held in May, to recommend preliminary that the traffic light has not been incorporated into the Sus. Now he will be in Turn Patiens, Professionals, Manager and the general population to express their opinion.
Lava
For the endocrinologist Maria Edna De Melo, director of the Department of Obesity of the Brazilian society of endocrinology and metabology (Sbem), the preliminary decision is not a right choice. “The dossier that has been sent had an effectiveness relationship in terms of costs that proved to be adequate, however, conitec’s evaluation has expanded the use, making it invaluable.”
He says that, in fact, the ideal is that the use of the continuous doctor, but there is evidence of benefits for a deadline. “Do you have to consider it: is it better to use it for a limited time or don’t use anything?”
Maria Edna, who also coordinates the defense commission of the Brazilian association for the study of obesity and metabolic syndrome (Abeso), underlines that in the country there is a structural problem as regards the lack of free drugs for the treatment of obesity.
Today there are five drugs approved by National Health Surveillance Agency (Anvisa) To treat the condition, with prices ranging from $ 30 to almost $ 2,000. “But none of them are incorporated into the public network,” complains about the doctor. “This opens inequality and structural faophobia,” he says.
The endocrinologist recalls that public consultation is also open on Incorporation of the liraglutide, as requested by Abeso and Sbem. In this case, the indication is for patients with obesity, diabetes and cardiovascular diseases. According to his first opinion, Conitec also recommended non -inclusion upwards.
According to her, the lack of these drugs, in addition to reducing the possibilities of therapeutic success, makes access to those who need the most “who have continuous money with access, while those who depend on the Su remains without an alternative,” he says.
What is traffic light
The 2.4 mg traffic light, sold with the commercial name WegovyIt is used to treat obesity or overweight associated with at least a comorbidity, such as type 2 diabetes or hypertension.
In practice, It works in two ways: Stimulating insulin production through pancreas, which helps to control blood glucose levels, essential for people who have type 2 diabetes and send signs of satiety to the hypothalamus, the brain region responsible for integration between endocrine and nervous systems.
This means that gastric emptying requires more time after a meal, leading to a prolonged sensation of satiety and reducing appetite.
Source: Terra
Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.
